SCHEMBL31076208

SCHEMBL31076208

FC1(F)CNc2ccccc2C1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ BRD4 O60885 2/20 0.43
▸ ALOX15 P16050 1/20 0.41
▸ HSD17B10 Q99714 1/20 0.41
▸ MAPT P10636 4/20 0.36
▸ NPC1 O15118 2/20 0.36
▸ KDM4E B2RXH2 2/20 0.36
▸ MEN1 O00255 2/20 0.36
▸ KMT2A Q03164 2/20 0.36
▸ AHR P35869 1/20 0.36
▸ PDK2 Q15119 1/20 0.36
▸ HSP90AA1 P07900 1/20 0.36
▸ THRB P10828 1/20 0.36
▸ HK1 P19367 1/20 0.36
▸ MAPK1 P28482 1/20 0.36
▸ RECQL P46063 1/20 0.36
▸ RAB9A P51151 1/20 0.36
▸ GALK1 P51570 1/20 0.36
▸ BLM P54132 1/20 0.36
▸ HKDC1 Q2TB90 1/20 0.36
▸ MAPK13 O15264 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1450879 0.80 MAPT (0.34) BRD4ALOX15HSD17B10MAPTNPC1
SCHEMBL1941368 0.80 KDM1A (0.39) BRD4ALOX15HSD17B10MAPTNPC1
SCHEMBL31076226 0.76 BRD4 (0.41) BRD4MEN1KMT2AAHR
SCHEMBL6327840 0.75 BRD4 (0.50) BRD4ALOX15HSD17B10MAPTNPC1
SCHEMBL20080101 0.75 BRD4 (0.43) BRD4ALOX15HSD17B10MAPTNPC1
SCHEMBL6754973 0.72 TDP2 (0.41) MAPTKDM4EMEN1KMT2AMAPK1
SCHEMBL14293599 0.71 TSHR (0.38) —
SCHEMBL1794222 0.71 BRD4 (0.40) BRD4ALOX15HSD17B10MAPTNPC1
SCHEMBL30376862 0.71 BRD4 (0.40) BRD4ALOX15HSD17B10MAPTNPC1
SCHEMBL23966212 0.69 BRD4 (0.52) BRD4ALOX15HSD17B10KDM4EMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4688791-A1 TRICYCLIC COMPOUNDS FOR THE TREATMENT OF CANCER F. Hoffmann-La Roche AG (CH) 2026-02-11 — — EP disclosed
US-20250376482-A1 TRICYCLIC COMPOUNDS FOR THE TREATMENT OF CANCER HOFFMANN-LA ROCHE INC. (US) 2025-12-11 — — US disclosed
US-12247036-B2 Tricyclic compounds for the treatment of cancer HOFFMANN-LA ROCHE INC. (US) 2025-03-11 — — US disclosed
US-20240417410-A1 TRICYCLIC COMPOUNDS FOR THE TREATMENT OF CANCER HOFFMANN-LA ROCHE INC. (US) 2024-12-19 — — US disclosed
EP-4469164-A1 TRICYCLIC COMPOUNDS FOR THE TREATMENT OF CANCER F. Hoffmann-La Roche AG (CH) 2024-12-04 — — EP disclosed
WO-2024208934-A1 TRICYCLIC COMPOUNDS FOR THE TREATMENT OF CANCER F. HOFFMANN-LA ROCHE AG (CH) 2024-10-10 — — WO disclosed
WO-2024169914-A1 TRICYCLIC COMPOUNDS FOR THE TREATMENT OF CANCER F. HOFFMANN-LA ROCHE AG (CH) 2024-08-22 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250376482-A1 TRICYCLIC COMPOUNDS FOR THE TREATMENT OF CANCER H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CCNI, TOP2B BRD4 245/4885ALOX15 3751/4885HSD17B10 712/4885
US-20240417410-A1 TRICYCLIC COMPOUNDS FOR THE TREATMENT OF CANCER H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CCNI, TOP2B BRD4 245/4885ALOX15 3751/4885HSD17B10 712/4885
US-12247036-B2 Tricyclic compounds for the treatment of cancer H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CCNI, TOP2B BRD4 245/4885ALOX15 3751/4885HSD17B10 712/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback